Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Atrial fibrillation is a common arrhythmia with age as a major stroke risk factor.
• Elderly patients (≥80 years) face increased ischemic and bleeding risks.
• Vitamin K antagonists (VKAs) reduce stroke but increase bleeding and require monitoring.

Purpose of the Study:

• To evaluate the benefits and safety of direct oral anticoagulants (DOACs) in patients aged 80 years and older.
• To address the lack of evidence regarding DOAC use in the very elderly population.
• To compare DOACs with VKAs in this specific high-risk group.

Main Methods:

• Literature review of existing studies on DOACs and VKAs in elderly populations.
• Analysis of data concerning efficacy and safety outcomes in patients aged 80+.
• Synthesis of current evidence to guide clinical practice.

Main Results:

• DOACs present fewer drug/food interactions and are easier to use than VKAs.
• Established DOAC efficacy and safety in the general population, but data for the very elderly (≥80) is scarce.
• Existing data on patients >75 years suggests potential benefits, but specific evidence for ≥80 is limited.

Conclusions:

• Further research is needed to clarify the specific benefits and safety profile of DOACs in patients aged 80 years and older.
• DOACs may offer advantages over VKAs due to ease of use and fewer interactions.
• Clinical decision-making for anticoagulation in the very elderly requires careful consideration of available evidence.